We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+34.16%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$913M
AUM Growth
+$115M
Cap. Flow
-$67.2M
Cap. Flow %
-7.37%
Top 10 Hldgs %
28.56%
Holding
108
New
15
Increased
30
Reduced
36
Closed
14

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$8.67M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$7.88M
3
ISRG icon
Intuitive Surgical
ISRG
+$6.74M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.19M
5
LIVN icon
LivaNova
LIVN
+$6.07M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$11.5M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$11.3M
3
TMO icon
Thermo Fisher Scientific
TMO
+$11.1M
4
COR icon
Cencora
COR
+$8.15M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.67M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
2 Financials 0.09%
3 Energy 0.09%
4 Technology 0.09%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
1
DELISTED
Esperion Therapeutics
ESPR
$39.4M 4.31%
660,000
+4,146
+0.6% +$186K
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$121B
$35M 3.84%
160,000
-26,000
-14% -$5.26M
NVCR icon
3
NovoCure
NVCR
$1.73B
$29.5M 3.23%
350,000
+10,000
+3% +$807K
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$28.1M 3.07%
775,000
-250,000
-24% -$7.67M
HUM icon
5
Humana
HUM
$43.7B
$24.6M 2.69%
67,000
+7,000
+12% +$2.22M
NKTR icon
6
Nektar Therapeutics
NKTR
$2.39B
$23.7M 2.6%
73,333
-6,667
-8% -$1.93M
BMY icon
7
Bristol-Myers Squibb
BMY
$133B
$21.8M 2.39%
340,000
-75,000
-18% -$4.3M
BSX icon
8
Boston Scientific
BSX
$69.5B
$20.4M 2.24%
451,668
+81,668
+22% +$3.42M
CI icon
9
Cigna
CI
$73.7B
$19.4M 2.13%
95,000
+15,000
+19% +$2.75M
ELV icon
10
Elevance Health
ELV
$81.5B
$18.7M 2.05%
62,000
+2,000
+3% +$550K
ABBV icon
11
AbbVie
ABBV
$443B
$18.6M 2.04%
210,000
+40,000
+24% +$3.32M
ABT icon
12
Abbott
ABT
$183B
$18M 1.97%
207,469
-12,645
-6% -$1.06M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.6B
$17.8M 1.95%
210,000
-80,491
-28% -$6.08M
ITCI
14
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$17.2M 1.88%
500,000
-350,000
-41% -$4.2M
UNH icon
15
UnitedHealth
UNH
$376B
$17.1M 1.87%
58,000
-19,000
-25% -$4.97M
AERI
16
DELISTED
Aerie Pharmaceuticals
AERI
$16.9M 1.85%
700,000
+225,000
+47% +$4.66M
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$16.1M 1.77%
125,000
+25,000
+25% +$2.41M
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15.3M 1.68%
210,000
+10,000
+5% +$607K
ALXN
19
DELISTED
Alexion Pharmaceuticals
ALXN
$15.3M 1.67%
141,319
-105,984
-43% -$11.3M
LIVN icon
20
LivaNova
LIVN
$4.4B
$15.1M 1.65%
200,000
+80,000
+67% +$6.07M
JAZZ icon
21
Jazz Pharmaceuticals
JAZZ
$15.9B
$15M 1.65%
100,805
-49,195
-33% -$6.69M
ABMD
22
DELISTED
Abiomed Inc
ABMD
$14.8M 1.63%
87,000
-33,000
-28% -$6.12M
IMMU
23
DELISTED
Immunomedics Inc
IMMU
$14.8M 1.62%
700,000
-150,000
-18% -$2.65M
LLY icon
24
Eli Lilly
LLY
$1.02T
$14.6M 1.61%
111,446
-38,554
-26% -$4.47M
MRK icon
25
Merck
MRK
$322B
$14.6M 1.59%
167,680
-57,640
-26% -$4.73M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rhenman & Partners Asset Management held 108 positions worth $913M, up 14% from $798M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $67.2M in Q4 2019, closing 14 positions and reducing 36 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Energy.

Against the trend, Rhenman & Partners Asset Management opened a new position in Axonics, Inc. Common Stock worth $9.14M.

  • Rhenman & Partners Asset Management's largest Q4 2019 buy was Axonics, Inc. Common Stock: 330,000 shares worth $9.14M.
  • Rhenman & Partners Asset Management added most to Guardant Health in Q4 2019, an estimated $8.67M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2019 reduction was CVS Health, cutting an estimated $11.5M.
  • Rhenman & Partners Asset Management fully exited Thermo Fisher Scientific in Q4 2019, selling an estimated $11.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $913M portfolio in Q4 2019.
  • Rhenman & Partners Asset Management opened 15 new positions and closed 14 in Q4 2019.
  • Rhenman & Partners Asset Management's portfolio value rose 14% quarter-over-quarter to $913M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.